Literature DB >> 15911702

High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells.

Giuseppe D Norata1, Elisa Callegari, Marta Marchesi, Giulia Chiesa, Per Eriksson, Alberico L Catapano.   

Abstract

BACKGROUND: HDL is endowed with cardiovascular protective activities. In addition to its role in reverse cholesterol transport, HDL influences different functions of endothelial cells. In the present study, we investigated in endothelial cells the genes involved in inflammation modulated by HDL. METHODS AND
RESULTS: Through cDNA array analysis, transforming growth factor (TGF)-beta2 appeared to be a gene responsive to HDL treatment in endothelial cells. Quantitative real-time polymerase chain reaction confirmed that HDL subfraction 3 selectively induces TGF-beta2 mRNA expression and protein release, whereas TGF-beta1 and TGF-beta3 were not affected. This effect was mainly PI3K/Akt dependent. Lysosphingolipids present in HDL such as sphingosine 1 phosphate and sphingosylphosphorylcholine mimicked the effects of the whole HDL. These results were confirmed in vivo in transgenic mice overexpressing human apolipoprotein (apo) A-I. Compared with apoA-I-knockout mice, phospho-Akt, phospho-ERK1/2, and TGF-beta2 expression was increased in the aorta of transgenic mice overexpressing human apoA-I. In addition, the expression of phospho-Smad2/3, the transcription factor activated by TGF-beta, is increased in transgenic mice compared with knockout mice.
CONCLUSIONS: Because TGF-beta possesses antiinflammatory properties and stabilizes the plaque, the results of the present work suggest a novel target for the antiatherosclerotic effect of HDL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15911702     DOI: 10.1161/CIRCULATIONAHA.104.472886

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

1.  Development of vascular smooth muscle contractility by endothelium-derived transforming growth factor β proteins.

Authors:  Chiwaka Kimura; Shuhei Konishi; Maki Hasegawa; Masahiro Oike
Journal:  Pflugers Arch       Date:  2013-07-26       Impact factor: 3.657

2.  Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein.

Authors:  Koichi Sato; Fumikazu Okajima
Journal:  World J Biol Chem       Date:  2010-11-26

Review 3.  Novel biological functions of high-density lipoprotein cholesterol.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2012-09-28       Impact factor: 17.367

Review 4.  High density lipoprotein: it's not just about lipid transport anymore.

Authors:  Scott M Gordon; Susanna Hofmann; David S Askew; W Sean Davidson
Journal:  Trends Endocrinol Metab       Date:  2010-11-08       Impact factor: 12.015

Review 5.  Regulation of signal transduction by HDL.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  J Lipid Res       Date:  2013-05-18       Impact factor: 5.922

Review 6.  Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies.

Authors:  Theodore Mazzone; Alan Chait; Jorge Plutzky
Journal:  Lancet       Date:  2008-05-24       Impact factor: 79.321

7.  High-density lipoproteins affect endothelial BMP-signaling by modulating expression of the activin-like kinase receptor 1 and 2.

Authors:  Yucheng Yao; Esther S Shao; Medet Jumabay; Ani Shahbazian; Sheng Ji; Kristina I Boström
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-10-23       Impact factor: 8.311

8.  Shoulder adhesive capsulitis and hypercholesterolemia: role of APO A1 lipoprotein polymorphism on etiology and severity.

Authors:  S Gumina; V Candela; A Castagna; M Carnovale; D Passaretti; T Venditto; G Giannicola; C Villani
Journal:  Musculoskelet Surg       Date:  2018-10-20

9.  High-density lipoproteins and the immune system.

Authors:  Hidesuke Kaji
Journal:  J Lipids       Date:  2013-01-30

10.  -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease.

Authors:  Ivano Baragetti; Giuseppe Danilo Norata; Cristina Sarcina; Andrea Baragetti; Francesco Rastelli; Laura Buzzi; Liliana Grigore; Katia Garlaschelli; Claudio Pozzi; Alberico Luigi Catapano
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.